NDC 43598-426

Bortezomib

Bortexomib

Bortezomib is a Intravenous; Subcutaneous Injection, Powder, Lyophilized, For Solution in the Human Prescription Drug category. It is labeled and distributed by Dr.reddy's Laboratories, Inc.. The primary component is Bortezomib.

Product ID43598-426_76eb5589-db8b-643c-8a38-7e600c4aea71
NDC43598-426
Product TypeHuman Prescription Drug
Proprietary NameBortezomib
Generic NameBortexomib
Dosage FormInjection, Powder, Lyophilized, For Solution
Route of AdministrationINTRAVENOUS; SUBCUTANEOUS
Marketing Start Date2022-07-26
Marketing CategoryANDA /
Application NumberANDA202963
Labeler NameDr.Reddy's Laboratories, Inc.
Substance NameBORTEZOMIB
Active Ingredient Strength4 mg/1
Pharm ClassesProteasome Inhibitor [EPC], Proteasome Inhibitors [MoA]
NDC Exclude FlagN
Listing Certified Through2023-12-31

Packaging

NDC 43598-426-60

1 VIAL, SINGLE-DOSE in 1 CARTON (43598-426-60) > 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, SINGLE-DOSE
Marketing Start Date2022-07-26
NDC Exclude FlagN
Sample Package?N

Drug Details

NDC Crossover Matching brand name "Bortezomib" or generic name "Bortexomib"

NDCBrand NameGeneric Name
0143-9098bortezomibbortezomib
0409-1700BortezomibBortezomib
0409-1703BORTEZOMIBBORTEZOMIB
0409-1704BORTEZOMIBBORTEZOMIB
0781-3258bortezomibbortezomib for injection
10019-991BORTEZOMIBbortezomib
25021-244BORTEZOMIBBORTEZOMIB
43598-426BortezomibBortexomib
43598-865BortezomibBortexomib
50742-484BortezomibBortezomib
51817-586Bortezomibbortezomib
55150-337BORTEZOMIBBORTEZOMIB
60505-6050BORTEZOMIBbortezomib
63323-721BortezomibBortezomib
63323-821BortezomibBortezomib
67184-0530BortezomibBortezomib
68001-534BortezomibBortezomib
68001-540BortezomibBortezomib
68001-541BortezomibBortezomib
70511-161Bortezomibbortezomib
70511-162Bortezomibbortezomib
70710-1411BORTEZOMIBBORTEZOMIB
70771-1708BORTEZOMIBBORTEZOMIB
70860-225Bortezomibbortezomib
71288-118BortezomibBortezomib
72205-183BortezomibBortezomib
72266-243Bortezomibbortezomib
72266-244Bortezomibbortezomib
63020-049VELCADEbortezomib

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.